References
- Lunenfeld B, Bilger W, Longobardi S, et al. The development of gonadotropins for clinical use in the treatment of infertility. Front Endocrinol. 2019;10:429.
- FDA. Highlights of prescribing information for gonal-f RFF redi-ject 2013 [cited 2022 Jan 18]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021684s036lbl.pdf
- Jeannerot F, Cusin A, Schertz J. Dose accuracy of the redesigned follitropin alfa pen injector for infertility treatment. Expert Opin Drug Deliv. 2016;13(12):1661–1669.
- EMA. GONAL-f: summary of product characteristics. The Netherlands: European Medicines Agency. 2023 [cited 2023 Oct 11]. Available from: https://www.ema.europa.eu/en/documents/product-information/gonal-f-epar-product-information_en.pdf
- EMA. Ovitrelle: summary of product characteristics. The Netherlands: European Medicines Agency; 2021 [cited 2022 Jan 18]. Available from: https://www.ema.europa.eu/en/documents/product-information/ovitrelle-epar-product-information_en.pdf
- EMA. Pergoveris: summary of product characteristics. The Netherlands: European Medicines Agency; 2021 [cited 2022 Jan 18]. Available from: https://www.ema.europa.eu/en/documents/product-information/pergoveris-epar-product-information_en.pdf
- Abbotts C, Salgado-Braga C, Audibert-Gros C. A redesigned follitropin alfa pen injector for infertility: results of a market research study. Patient Prefer Adherence. 2011;5:315–331. doi:10.2147/PPA.S21421
- Kivitz A, Cohen S, Dowd JE, et al. Clinical assessment of pain, tolerability, and preference of an autoinjection pen versus a prefilled syringe for patient self-administration of the fully human, monoclonal antibody adalimumab: the TOUCH trial. Clin Ther. 2006;28(10):1619–29. doi: 10.1016/j.clinthera.2006.10.006
- Longobardi S, Seidler A, Martins J, et al. An evaluation of the use and handling errors of currently available recombinant human follicle-stimulating hormone pen injectors by women with infertility and fertility nurses. Expert Opin Drug Deliv. 2019;16(9):1003–1014.
- Dallagiovanna C, Mensi L, Di Gesaro L, et al. Satisfaction and usability of the recombinant chorionic gonadotropin prefilled pen: a survey in Italy. Drugs Context. 2022;11:1–4. doi: 10.7573/dic.2021-10-3
- Choi BC, Zhou C, Ye H, et al. A comparative, observational study evaluating dosing characteristics and ovarian response using the recombinant human follicle-stimulating hormone pen injector with small-dose dial in assisted reproductive technologies treatment in Asia: IMPROVE study. Reprod Biol Endocrinol. 2022;20(1):15. doi: 10.1186/s12958-021-00882-2
- Schertz J, Worton H. Patient evaluation of the redesigned follitropin alfa pen injector. Expert Opin Drug Deliv. 2017;14(4):473–81. doi: 10.1080/17425247.2017.1289174.
- ISO. ISO 11608-1: needle-based injection systems for medical use — requirements and test methods — part 1: needle-based injection systems 2014 [cited 2022 Jan 18]. Available from: www.iso.org/standard/65021.html
- FDA. Technical considerations for pen, jet, and related injectors intended for use with drugs and biological products. 2020 [cited 2022 Jan 18]. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/technical-considerations-pen-jet-and-related-injectors-intended-use-drugs-and-biological-products
- Mahony MC, Patterson P, Hayward B, et al. Human factors engineering and design validation for the redesigned follitropin alfa pen injection device. Expert Opin Drug Deliv. 2015;12(5):715–25. doi: 10.1517/17425247.2015.1033395.
- Christen M, Schertz JC, Arriagada P, et al. The redesigned follitropin alpha pen injector for infertility treatment. Expert Opin Drug Deliv. 2011;8(6):833–839. doi:10.1517/17425247.2011.581658
- Schertz J, Worton H. Nurse evaluation of the redesigned fertility pen injector: a questionnaire-based observational survey. Expert Opin Drug Deliv. 2018;15(5):435–42. doi:10.1080/17425247.2018.1450386
- Saunders H, Schertz JC, Hecker C, et al. The recombinant human chorionic gonadotropin prefilled pen: results of patient and nurse human factors usability testing. Expert Opin Drug Deliv. 2012;9(8):893–900. doi:10.1517/17425247.2012.698607
- Saunders H, Bjargestad Lamp L, Donat H, et al. Risk of dosing errors in ART treatment: user experience of single- vs multi-use follitropin alfa pens. Expert Opin Drug Deliv. 2021;18(5):643–54. doi:10.1080/17425247.2021.1863944